Earnings Briefs: Sanofi, Amgen, Aegerion, Vertex, MorphoSys, Allergan
Executive Summary
Launches go well for Vertex’s Kalydeco and Aegerion’s Juxtapid, but for Sanofi, the pipeline hits keep on coming.
You may also be interested in...
Allergan’s Manufacturing Challenges Produce Second Levadex “Complete Response” Letter
FDA again cites inspection issues related to a third-party facility where the product canister for the migraine drug is manufactured, as well as the manufacturing process itself; Allergan says it recently completed an acquisition of that third-party firm, thereby bringing the inhaled treatment’s manufacturing in-house.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.